Independent confirmation of juvenile idiopathic arthritis genetic risk loci previously identified by immunochip array analysis by unknown
Chiaroni-Clarke et al. Pediatric Rheumatology 2014, 12:53
http://www.ped-rheum.com/content/12/1/53SHORT REPORT Open AccessIndependent confirmation of juvenile idiopathic
arthritis genetic risk loci previously identified by
immunochip array analysis
Rachel C Chiaroni-Clarke1,2, Jane E Munro3,4, Raul A Chavez1,2, Angela Pezic5, Roger C Allen3,4,
Jonathan D Akikusa3,4, Susan E Piper6, Richard Saffery7,2, Anne-Louise Ponsonby5,2 and Justine A Ellis1,2*Abstract
Background: Our understanding of the genetic factors underlying juvenile idiopathic arthritis (JIA) is growing, but
remains incomplete. Recently, a number of novel genetic loci were reported to be associated with JIA at (or near)
genome-wide significance in a large case–control discovery sample using the Immunochip genotyping array. However,
independent replication of findings has yet to be performed. We therefore attempted to replicate these newly
identified loci in the Australian CLARITY JIA case–control sample.
Findings: Genotyping was successfully performed on a total of 404 JIA cases (mean age 6.4 years, 68% female)
and 676 healthy child controls (mean age 7.1 years, 42% female) across 19 SNPs previously associated with JIA. We
replicated a significant association (p < 0.05, odds ratio (OR) in a direction consistent with the previous report) for
seven loci, six replicated for the first time - C5orf56-IRF1 (rs4705862), ERAP2-LNPEP (rs27290), PRR5L (rs4755450),
RUNX1 (rs9979383), RUNX3 (rs4648881), and UBE2L3 (rs2266959).
Conclusions: We have carried out the first independent replication of association for six genes implicated in JIA
susceptibility. Our data significantly strengthens the evidence that these loci harbor true disease associated
variants. Thus, this study makes an important contribution to the growing body of international data that is
revealing the genetic risk landscape of JIA.
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Juvenile Idiopathic Arthritis (JIA) is the most common
rheumatic disease in children [1], yet there are relatively
few confirmed disease associated loci, and we are there-
fore limited in our understanding of the overall genetic
architecture [2,3]. Only two genome-wide association
studies have been published for JIA [4,5], limited by
sample size and/or genomic coverage. In these studies, a
discovery sample was used to identify potential risk loci,
and then an independent replication sample was used to
confirm the findings. In both studies, a number of loci
were identified as associated with JIA in the discovery* Correspondence: justine.ellis@mcri.edu.au
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article, unless otherwise stated.sample that were unable to be replicated in the validation
sample [4,5]. This highlights the importance of independ-
ent replication in determining true disease associated loci.
In 2013, Hinks et al. published the most successful
genetic association study for JIA to date [6], using the
Immunochip [7]; a genotyping array specifically designed
to densely capture variation at immune-related genetic
loci. The study further validated the well-established
associations of HLA, PTPN22 and PTPN2 with JIA, in
addition to confirming the involvement of other loci
such as STAT4 with JIA, that were previously associated
with the disease, but not at a genome-wide level of sig-
nificance (p < 5 × 10−8)[6]. More notably, the same study
identified a suite of novel JIA risk loci reaching either
genome-wide significance, or a genome-wide ‘suggest-
ive’ level of significance (p < 1 × 10−6) [6]. However, in
order to maximize statistical power for discovery, allCentral. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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replication sample was available to confirm these novel
associations. Therefore, we aimed to confirm the in-
volvement of these new JIA risk loci in an independent
sample of JIA cases and healthy child controls drawn
from the CLARITY JIA case–control study in Melbourne
Australia [8,9].
We selected 22 single nucleotide polymorphisms (SNPs)
from the JIA Immunochip association study [6], for po-
tential replication. SNPs that are established susceptibility
loci for JIA [4], or that have previously been associated in
our sample [8] (either the SNP itself or a SNP in high link-
age disequilibrium) were omitted. Two SNPs selected for
inclusion subsequently failed assay design and were there-
fore also excluded. Reasons for exclusion are listed in
Additional file 1: Table S1. Genotyping of the remaining
20 SNPs was attempted in a total of 408 JIA cases and 687
controls drawn from CLARITY, using the Sequenom
MassARRAY system (assay design details available from
the authors). Following exclusion of individuals and SNPs
not meeting quality control thresholds (<90% call rate for
individuals or SNPs, and departure from Hardy Weinberg
equilibrium p < 0.001), genotype data was successfully








13q14 rs34132030 T 0.30/0.30 0.82 1.02 (0
AFF3-LONRF2 rs6740838 T 0.44/0.41 0.25 1.11 (0
ANKRD55 rs71624119 A 0.20/0.23 0.10 0.83 (0
ATP8B2-IL6R rs11265608 A 0.08/0.07 0.50 1.12 (0
C5orf56-IRF1 rs4705862 T 0.42/0.45 0.11 0.87 (0
CCR1-CCR3 rs79893749 T 0.09/0.11 0.10 0.78 (0
ERAP2-LNPEP rs27290 G 0.47/0.39 0.00021 1.40 (1
FAS rs7069750 G 0.47/0.45 0.19 1.12 (0
IL2-IL21 rs1479924 G 0.27/0.28 0.54 0.94 (0
IL2RB rs2284033 A 0.40/0.43 0.24 0.90 (0
IL6 rs7808122 T 0.41/0.40 0.76 1.03 (0
JAZF1 rs10280937 C 0.15/0.14 0.77 1.04 (0
LTBR rs2364480 C 0.26/0.27 0.65 0.96 (0
PRR5L rs4755450 A 0.34/0.38 0.043 0.83 (0
RUNX1 rs9979383 C 0.32/0.37 0.013 0.79 (0
RUNX3 rs4648881 A 0.48/0.50 0.37 0.92 (0
TYK2 rs34536443 C 0.02/0.03 0.10 0.63 (0
UBE2L3 rs2266959 T 0.23/0.19 0.040 1.25 (1
ZFP36L1 rs12434551 T 0.46/0.45 0.61 1.05 (0
aModel providing most significant P value: A = allelic, D = dominant, G = genotypic, R =
bImmunochip model: A = additive, D = dominant.
cEvidence for replication Y = yes N = no S = suggestive * = opposite direction of effe
Bold = reached genome-wide significance in Immunochip paper.female) and 676 healthy child controls (mean age 7.1 years,
42% female) across 19 SNPs (listed in Table 1). One SNP,
rs66718203 at PRM1-RM12, failed genotyping quality
control and was excluded from further analysis. We re-
genotyped a random 10% selection of samples across all
SNPs and achieved a genotype concordance rate of >99%.
Allelic, genotypic, additive (Cochrane-Armitage test for
trend), dominant and recessive association tests were per-
formed using PLINK v1.07 [10]. We considered p < 0.05
for any test, along with an allelic odds ratio (OR) in a dir-
ection consistent with the previous report, as evidence of
replication. As these SNPs had a priori evidence for asso-
ciation, we did not adjust the p values for multiple testing.
Table 1 shows the ORs and p values for allelic associ-
ation tests, as well as the ‘best test’ model and correspond-
ing p value. These are shown alongside the reported ORs,
p value, and model from the Immunochip study. Figure 1
shows a forest plot of the allelic odds ratios generated in
the CLARITY sample compared to the Immunochip study
ORs for all SNPs tested. We report replication of associ-
ation for six genes (SNPs) in our sample - AFF3-LONRF2
(rs6740838), C5orf56-IRF1 (rs4705862), ERAP2-LNPEP
(rs27290), PRR5L (rs4755450), RUNX1 (rs9979383) and
UBE2L3 (rs2266959). A further seven genes (SNPs) showedBest Immunochip Replicationc
5% CI) Pa Pb OR (95% CI)
.85-1.24) 0.68 D 1.77 × 10−7 A 1.18(1.11-1.26) N
.93-1.32) 0.042 R 8.83 × 10−7 D 1.25(1.14-1.37) Y
.67-1.03) 0.081 R 4.40 × 10−11 A 0.78(0.73-0.84) S
.81-1.55) 0.50 T 2.75 × 10−8 D 1.33(1.20-1.47) N
.73-1.04) 0.033 D 1.02 × 10−8 A 0.84(0.79-0.89) Y
.58-1.05) 0.10 A 1.88 × 10−7 A 0.78(0.72-0.86) S
.17-1.66) 0.00021 A 7.50 × 10−9 D 1.32(1.20-1.45) Y
.94-1.34) 0.19 A 2.93 × 10−8 A 1.18(1.11-1.25) S
.77-1.15) 0.16 R 6.24 × 10−11 A 0.79(0.74-0.85) S
.75-1.08) 0.18 D 1.55 × 10−8 A 0.84(0.79-0.89) S
.86-1.23) 0.59 R 5.80 × 10−8 A 1.19(1.11-1.25) N
.81-1.33) 0.74 D 6.60 × 10−7 A 1.25(1.15-1.37) N
.78-1.16) 0.49 R 5.10 × 10−8 A 1.20(1.12-1.28) N
.69-0.99) 0.042 D 3.35 × 10−7 D 0.80(0.74-0.87) Y
.66-0.95) 0.013 A 1.06 × 10−8 D 0.78(0.72-0.85) Y
.78-1.10) 0.19 D 4.66 × 10−7 A 1.16(1.10-1.23) S*
.36-1.10) 0.10 A 1.00 × 10−10 A 0.56(0.47-0.67) S
.01-1.55) 0.036 T 6.20 × 10−9 D 1.24(1.15-1.33) Y
.88-1.25) 0.50 R 1.59 × 10−8 D 0.77(0.71-0.85) N
recessive, T = trend (Cochrane-Armitage Trend Test, also referred to as additive).
















































































































CLARITY OR CLARITY 95% CI
Immunochip OR Immunochip 95% CI
Figure 1 Forest Plot comparing CLARITY allelic ORs with
published Immunochip ORs for each SNP genotyped.
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direction and a p < 0.2) - ANKRD55 (rs71624119), CCR1-
CCR3 (rs79893749), FAS (rs7069750), IL2-IL21 (rs1479924),
IL2RB (rs2284033), RUNX3 (rs4648881) and TYK2
(rs34536442).
We re-analysed the data after restricting the samples
to those of European descent to ensure associations were
not being masked by differences in ethnicity between the
prior study and our own. Only those individuals who
identified all four grandparents as European were in-
cluded. Individuals with a non-European grandparent or
any missing information were excluded. This restriction
criterion reduced our sample size to 229 cases (mean
age 6.2 years, 70% female) and 418 controls (mean age
7.2 years, 40% female). The results of this analysis are
detailed in Additional file 1: Table S2. Overall, the results
of this analysis did not considerably differ from the en-
tire sample, with a few exceptions. Of note, RUNX3
(rs4648881), which had a suggestive association in the
total sample, showed a significant association in the
European-only sample. Furthermore, ZFP36L1 (rs12434551)
showed significant association with JIA in the European-
only sample, suggesting it may be particularly sensitive to
ethnicity. However, our reported SNP (T) differs to the
previously reported SNP (A), and the association is in the
opposite direction. As this SNP is an A/T transversion
with frequencies of both alleles near 50% we cannot deter-
mine whether the direction of effect difference is due to
allele reversal, and thus replicates the prior result, or the
result of analysing different DNA strands between the two
studies, in which case the risk locus is not replicated. Two
genes that were significantly associated in the entire sam-
ple, PRR5L (rs4755450), and AFF3-LONRF2 (rs6740838),
were no longer significant in the European-only analysis,
and C5orf56-IRF1 (rs4705862) showed only suggestive sig-
nificance. Given that the reduced sample size likely re-
sulted in a reduction in statistical power, small movementsin the ORs and p values are not unexpected, and this result
is unlikely to indicate failure to replicate.
We have replicated the association of AFF3-LONRF2
(rs6740838), and showed suggestive association of ANKRD55
(rs71624119) and IL2-IL21 (rs1479924), which all had evi-
dence of association with JIA prior to the Immunochip
study [11-13], although the samples used in those prior
studies significantly overlapped with those used in the
Immunochip study (i.e. the replication efforts were not in-
dependent). A recent independent study by Reinards et al.
[14] also examined evidence for association of JIA with
SNPs at ANKRD55 and AFF3 that are highly correlated
(r2 ~ 0.9) with the Immunochip SNPs at these genes. The
association with ANKRD55 was replicated, further sup-
porting a role for this gene in JIA risk. The association
with AFF3 was not replicated, although the direction of ef-
fect is consistent across studies.
Although our study has been able to confirm association
of a number of Immunochip-identified genes with JIA
risk, lack of replication in our study cannot be taken as
evidence to refute association for a number of reasons.
First, our sample size is much smaller than that used by
the Immunochip study, and therefore has lower statistical
power to detect association. This is somewhat offset by
the more relaxed level of significance required for replica-
tion, compared to that required in the discovery study.
Second, the Immunochip study was restricted to oligoarti-
cular and polyarticular RF negative JIA. Here we have
considered all JIA subtypes together. We chose not to per-
form subtype specific analyses, as the benefit of reduced
heterogeneity would be offset by the reduction in statis-
tical power associated with reduced sample size. The fact
that the associations identified in this study were still
detectable when all subtypes were considered together
suggests common pathways to disease in all subtypes
(potential ‘pan-JIA’ genes). Such genes are not unexpected,
given the significant overlap amongst disease risk genes
across far more clinically heterogeneous forms of auto-
immune disease [15]. Despite the sample size and case
heterogeneity limitations of our study, it is worth noting
that a number of the associations that we have failed to
replicate only carried a suggestive level of association in
the original study, and therefore our lack of replication
may well be indicating lack of true association.
This study has further confirmed association of JIA
with seven genetic loci, six of which have now been repli-
cated for the first time (C5orf56-IRF1 (rs4705862), ERAP2-
LNPEP (rs27290), PRR5L (rs4755450), RUNX1 (rs9979383),
RUNX3 (rs4648881), and UBE2L3 (rs2266959)). For an
additional six genes, we generated weaker indication of
association, further supporting (but not yet confirming)
involvement in JIA risk. Further analysis of these loci in
other independent samples will assist in clarifying their
role in disease susceptibility. Overall, our study makes
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national data that is revealing the genetic risk landscape
of this paediatric autoimmune disease.
Additional file
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CLARITY SNP replication results in European---restricted cohort, case
n=220 control n=418.
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